Clincosm LogoSign in Get a demo

nsclc

Showing 26 - 50 of 360
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Resectable Stage II-IIIB Driver Gene-negative Non-small Cell

Not yet recruiting
  • NSCLC
    • Changsha, Hunan, China
      Hunan Cancer Hospital
    Aug 6, 2023

    Aspirin in Combination With Trametinib and Dabrafenib

    Not yet recruiting
    • NSCLC
    • +4 more
    • Combind asprin with Trametinib and Dabrafenib
    • (no location specified)
    Aug 4, 2023

    NSCLC Trial in Guangzhou (PEF, Anti-PD-1 mAb)

    Recruiting
    • NSCLC
    • PEF
    • Anti-PD-1 monoclonal antibody
    • Guangzhou, Guangdong, China
      The first Affiliated Hospital of Guangzhou Medical University
    Aug 3, 2023

    NSCLC Trial (Idylla EGFR_IUO/3.20 Mutation Test)

    Not yet recruiting
    • NSCLC
    • Idylla EGFR_IUO/3.20 Mutation Test
    • (no location specified)
    Jul 24, 2023

    NSCLC, EGFR Activating Mutation, Brain Metastases Trial in Beijing (TY-9591, Osimertinib)

    Not yet recruiting
    • NSCLC
    • +2 more
    • Beijing, Beijing, China
      National Cancer Center/Cancer Hospitial,Chinese Academy of Medic
    Jul 9, 2023

    NSCLC, NSCLC Trial in Guangzhou (Apatinib + Fluzoparib, Apatinib + Fluzoparib + Adebrelimab)

    Not yet recruiting
    • NSCLC
    • Non-small Cell Lung Cancer
    • Apatinib + Fluzoparib
    • Apatinib + Fluzoparib + Adebrelimab
    • Guangzhou, Guangdong, China
      Sun Yat-Sen University Cancer Center
    Jun 27, 2023

    Omitting Clinical Target Volume in Radical Treatment of

    Not yet recruiting
    • Immunotherapy
    • +3 more
    • IMRT+adjuvant immunotherapy
    • (no location specified)
    Jun 9, 2023

    NSCLC Trial (HLX208, Itraconazole 200 mg, Rifampicin)

    Not yet recruiting
    • NSCLC
    • (no location specified)
    Jun 5, 2023

    NSCLC, HNSCC, Melanoma Trial (CJRB-101, Pembrolizumab injection)

    Not yet recruiting
    • NSCLC
    • +5 more
    • (no location specified)
    Jun 1, 2023

    NSCLC, Neoadjuvant Therapy Trial in Hangzhou (Serplulimab and neoadjuvant therapy, surgical resection of lung cancer)

    Recruiting
    • NSCLC
    • Neoadjuvant Therapy
    • Serplulimab and neoadjuvant therapy
    • surgical resection of lung cancer
    • Hangzhou, China
      2nd Affiliated Hospital, School of Medicine, Zhejiang University
    May 22, 2023

    Solid Tumor, Adult, NSCLC, Advanced Cancer Trial (Adagrasib, nab-Sirolimus)

    Not yet recruiting
    • Solid Tumor, Adult
    • +4 more
    • (no location specified)
    Apr 24, 2023

    Invasive Ductal Breast Carcinoma, Invasive Ductal Breast Carcinoma Stage IV, Lobular Breast Carcinoma Trial in United States

    Recruiting
    • Invasive Ductal Breast Carcinoma
    • +14 more
    • Stereotactic body radiotherapy
    • Lattice Radiation Therapy
    • Basking Ridge, New Jersey
    • +6 more
    Apr 20, 2023

    NSCLC Trial in Beijing (RC108)

    Not yet recruiting
    • NSCLC
    • Beijing, Beijing, China
      Cancer Hospital Chinese Academy of Medical Sciences
    Apr 18, 2023

    NSCLC Trial (Atezolizumab, Tiragolumab)

    Not yet recruiting
    • NSCLC
    • (no location specified)
    Apr 5, 2023

    NSCLC Trial in Shanghai (SBRT+LDRT, Toripalimab, Chemotherapy drug)

    Recruiting
    • NSCLC
    • SBRT+LDRT
    • +2 more
    • Shanghai, Shanghai, China
      Shanghai Chest Hospital
    Apr 2, 2023

    NSCLC, Non-small Cell Carcinoma, Histiocytic Tumor Trial (BDTX-4933)

    Not yet recruiting
    • Non-small Cell Lung Cancer
    • +32 more
    • (no location specified)
    Mar 30, 2023

    Aumolertinib, Anlotinib, TP53 Trial (Aumolertinib,Anlotinib)

    Not yet recruiting
    • Aumolertinib
    • +4 more
    • (no location specified)
    Mar 8, 2023

    NSCLC Trial in Singapore (Oral S-1 + Oral Osimertinib)

    Not yet recruiting
    • NSCLC
    • Oral S-1 + Oral Osimertinib
    • Singapore, Singapore
      National Cancer Center Singapore
    Mar 6, 2023

    Advanced Solid Tumor, NSCLC Trial in Shanghai (XZB-0004)

    Not yet recruiting
    • Advanced Solid Tumor
    • NSCLC
    • Shanghai, Shanghai, China
      Shanghai Pulmonary Hospital
    Mar 5, 2023

    NSCLC Trial (PM8002, Placebo, Carboplatin)

    Not yet recruiting
    • NSCLC
    • (no location specified)
    Feb 23, 2023

    NSCLC, NSCLC, PD-1 Trial in Beijing (F520, Pemetrexed, Carboplatin)

    Not yet recruiting
    • Non-small Cell Lung Cancer
    • +2 more
    • Beijing, China
      Cancer Hospital, Chinese Academy of Medical Sciences
    Feb 22, 2023

    Solid Tumor, Adult, Solid Tumor, Pancreatic Cancer Trial in United States (A2B530, xT-Onco with HLA-LOH Assay)

    Not yet recruiting
    • Solid Tumor, Adult
    • +15 more
    • A2B530
    • xT-Onco with HLA-LOH Assay
    • Duarte, California
    • +6 more
    Feb 10, 2023

    NSCLC Trial (JDQ443)

    Not yet recruiting
    • NSCLC
    • (no location specified)
    Feb 2, 2023

    Lung Cancer, Organoid, NSCLC Trial in Wuxi (Antitumor therapy guided by organoid drug sensitivity test)

    Recruiting
    • Lung Cancer
    • +2 more
    • Antitumor therapy guided by organoid drug sensitivity test
    • Wuxi, Jiangsu, China
      Affiliated Hospital of Jiangnan University
    Feb 2, 2023

    NSCLC Trial (food, fast)

    Not yet recruiting
    • NSCLC
    • food
    • fast
    • (no location specified)
    Jan 24, 2023